AzTrials
AzTrials

Acute Myeloid LeukaemiaLEAPNCT06928909

Leukemia Adapted Protocol

An observational study of Acute Myeloid Leukaemia, run by Baylor College of Medicine at 1 site in Malawi.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In resource-constrained settings such as Malawi, survival rates for pediatric acute myeloid leukemia (AML) are dismally low compared to high-resource environments. This disparity highlights the urgent need for feasible treatment protocols tailored to the realities of these regions where most children with cancer are… Read more about this study

Who is it for?
Ages Up to 18 years
Conditions the study is for
Acute Myeloid Leukaemia
What is being tested?
Intensity-adapted pediatric acute myeloid treatment guidelines
How many people
30 participants
Where
1 siteMalawi
Study dates
1 Jan 2025to 31 Dec 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: All patients with de novo AML presenting to Kamuzu Central Hospital in Lilongwe, Malawi.

Who may be able to join

  • Age Patients must be <18 years of age at time of study enrollment.
  • Diagnosis
  • Patients must be diagnosed with de novo AML according to 2022 WHO 5th Edition classification with or without extramedullary disease. Patients must have one of the following:
  • Bone marrow myeloblasts ≥20%. In cases of dry taps due to fibrosis, myeloblast percentage can be estimated from a bone marrow biopsy core specimen. Due to unavailable molecular/cytogenetic diagnostics in Malawi, patients with <20% bone marrow myeloblasts can be included in the study at the discretion of the treating oncologist with rationale documented.
  • In cases where a bone marrow evaluation is not safe/feasible, a peripheral blood sample may be used with a documented absolute myeloblast percentage of ≥1000/μL calculated based on a total white blood cell count and percentage circulating blasts.
  • Therapy Patients must begin treatment according to the 2023 KCH AML therapy CPG.

Who cannot join

  • Patients with any of the following conditions or criteria will be excluded from the study:
  • Juvenile myelomonocytic leukemia
  • Transient myeloproliferative disorder
  • Acute promyelocytic leukemia
  • Mixed phenotype acute leukemia
  • Trisomy 21
Show all 13Show fewer
  • Current pregnancy
  • Previous or concurrent malignancy
  • Isolated myeloid sarcoma
  • Patients previously treated with antineoplastic therapy with the following exceptions:
  • Hydroxyurea
  • Corticosteroids
  • Intrathecal chemotherapy at diagnosis

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Casey McAtee, M.D., M.P.H. contact

+1 251-605-5370

casey.mcatee@bcm.edu

Malawi1 site, 1 recruiting

  • Kamuzu Central Hospital

    Lilongwe, Lilongwe

    Casey McAtee, M.D., M.P.H., +265 981189581, casey.mcatee@bcm.edu

    Recruiting

Other trials in Malawi

About this study

Official title: Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi

In resource-constrained settings such as Malawi, survival rates for pediatric acute myeloid leukemia (AML) are dismally low compared to high-resource environments. This disparity highlights the urgent need for feasible treatment protocols tailored to the realities of these regions where most children with cancer are treated. In 2023, after reviewing favorable clinical trials results in other resource-limited settings, the Kamuzu Central Hospital (KCH) pediatric cancer unit adopted an evidence-based intensity-adapted clinical practice guideline (CPG) developed by the International Society of Paediatric Oncology (SIOP) as its standard of care for the treatment of pediatric AML, aiming to balance curative intent with manageable toxicity. The current study is a prospective evaluation of outcomes of standard of care in Malawi using the SIOP CPG in a real-world setting.

The LEAP study aims to assess the implementation of the SIOP AML guidelines at KCH in an effort to continually improve outcomes in Malawi. The study is an observational-implementation design with a composite effectiveness-implementation outcome called Implementation Success. Implementation Success combines feasibility, the ability of patients to complete all aspects of the CPG, with effectiveness, the ability to maintain historical rates of complete remission of 40% at the treatment center.

Read more

This prospective cohort study will enroll children under 18 years diagnosed with de novo AML at KCH. Implementation Success will be the primary endpoint, with secondary endpoints including CPG fidelity, long-term survival, adverse events, and hematologic recovery times. Patient-reported outcomes will also be collected to assess the impact of treatment on quality of life.

This will be the first prospective study of pediatric AML in sub-Saharan Africa, providing critical data on the management of AML in low-resource settings. By assessing the implementation of a context-adapted CPG, the study will contribute to the global effort to improve pediatric AML outcomes in resource-constrained environments. The findings will serve to guide practitioners in Malawi and similar settings, and the data generated will be invaluable for future clinical decisions and CPG development.

Read the detailed description

Participants:

  • All patients with have de novo AML presenting to Kamuzu Central Hospital (KCH) in Lilongwe, Malawi will be offered enrollment into the study.
  • Patients must be <18 years of age at time of study enrollment.
  • Patients must begin treatment according to the 2023 KCH AML therapy CPG.
  • All patients at the treating center receiving curative-intent therapy for AML are treated on the 2023 KCH AML standard of care CPG based on the SIOP AML guidelines, independent of participation in research.
  • Patients should ideally be consented for data collection within one week of confirmatory diagnosis to ensure highest quality of prospective data collection.

The therapy guideline used at KCH is based upon the published international guidelines for treating pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care at KCH.

Data Collection Schedule:

All study measurements in this study are routinely captured as part of clinical care. No additional clinical studies will be obtained from patients as a consequence of enrollment onto the LEAP study.

  1. On-treatment schedule Patients are routinely admitted inpatient to the pediatric cancer unit at the start of each chemotherapy cycle. Patients remain inpatient according to standard practices of the unit until they no longer require routine blood product transfusions and their absolute neutrophil count is rising. Patients are discharged home for ~1 week prior to returning to start the subsequent cycle, but generally no later than 2 weeks from discharge. Required Data Items are all routinely obtained as part of standard of care:
  • Bone marrow aspirate with morphology +/- trephine biopsy
  • Bone marrow flow cytometry OR immunohistochemistry
  • Lumbar puncture with cerebrospinal fluid cell count \& morphological evaluation
  • Leukemia cytogenetics
  • Lanksy score
  • Weight, height, MUAC
  • History \& physical
  • Complete blood count
  • Serum electrolytes
  • Confirmation of HIV serostatus (standard of care for all pediatric patients in Malawi)
  • Chest X-ray
  • Echocardiogram
  • Adverse event monitoring
  • PROMIS-25 parent \& patient questionnaire (additional research-only evaluation)
  • REDCap data upload
  1. Post-treatment schedule Patients will be followed up by telephone monthly for the first six months off therapy. In-person visits routinely occur at 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months following completion of therapy. They are followed annually thereafter.

Required Data Items:

  • History and confirmation of vital status
  • Physical exam
  • Complete/full blood count
  • PROMIS-25 questionnaire
  • REDCap data upload

Statistical analysis:

Sample size determination of this study is based on accrual capacity of the study site, not from statistical power. Based on diagnoses over the previous three years at Kamuzu Central Hospital in Malawi, the investigators expect at least 10 de novo cases/year of AML.

Primary Endpoint

CPG Implementation Success will be a composite endpoint comprised of:

  1. Feasibility: proportion of patients completing the CPG
  2. Effectiveness: proportion of patients in complete remission (CR) by the end of Induction

Implementation will be deemed successful if 1) ≥50% of patients are able to complete the CPG; AND 2) The historical benchmark of end-of-induction complete remission (CR) of 40% is maintained.

Rates of CR (effectiveness outcome) and CPG completion (implementation outcome) will be monitored continuously by the study statistician team using an adaptation of the method of Ivanova and colleagues. This method provides a Pocock-type boundary so that the probability of crossing the boundary is at most 5% when the true rate of the event crosses the acceptable threshold. For the effectiveness threshold of CR, we will use the established historical rate of CR of 40% achieved on the old standard of care for AML in Malawi. The probability of boundary crossing rises to 24%, 68%, and 98% if the CR rate drops to 30%, 20%, and 10%, respectively, with corresponding accruals of N=28, 22, and 14. Similarly, for rate of CPG completion, we will use a threshold of 50%. The probability of boundary crossing rises to 22%, 59%, and 92% if the rate of completion rate drops to 40%, 30%, and 20%, respectively, with corresponding expected accruals of N=27, 22, and 15.

Criteria for completing the CPG are:

  1. Completing all required chemotherapy cycles (Induction 1, Induction 2, Consolidation 1, Consolidation 2) and achieving transfusion independence following Consolidation 2 outside of the setting of relapse or bone marrow failure (in which case therapy will be considered complete for the purposes of the study outcome). Note that pre-phase is not required for completion.
  2. Completion of Inductions 1 and 2 but not in CR at the end of Induction.
  3. Completion of Inductions 1 and 2 having achieved CR by the end of Induction 2 but having had relapse prior to completing Consolidation 2.
  4. All patients with early mortality (≤42 days), treatment-related mortality, or treatment abandonment of curative-intent therapy will be considered incomplete.
  5. Patients removed from curative-intent therapy due to toxicity will be considered incomplete.

Complete Remission is defined as <5% myeloblasts on bone marrow evaluation.

Secondary Endpoints

  • Event-free, relapse-free, and overall survival at 12 \& 24 months from diagnosis
  • Proportion of patients with CTCAE ≥3 adverse events
  • Patient-reported outcomes at diagnosis, end of induction, end of therapy, and 6 months post-therapy.
  • Cytogenetic characteristics of myeloblasts
  • Proportion of discrete treatment and supportive care CPG elements received/completed as prescribed
Being tested
Intensity-adapted pediatric acute myeloid treatment guidelines
Keywords
Pediatric Acute Myeloid Treatment, Acute myeloid leukemia (AML)
Medical subject headings
Leukemia, Myeloid, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intensity-adapted pediatric acute myeloid treatment guidelinesOther

    This is an observational study evaluating the current standard of care AML therapy in Malawi. The therapy guideline used is an adaptation of the International Society of Paediatric Oncology (SIOP) guidelines for pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care in Malawi for all patients with AML. Receipt of this therapy guideline is independent of participation in research.

Study groups in NCT06928909
Study groupRoleWhat they receive
All patients with de novo AMLAll patients with de novo AML presenting to Kamuzu Central Hospital in Lilongwe, Malawi will be offered enrollment into the study.
Receives: Other: Intensity-adapted pediatric acute myeloid treatment guidelines

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determine the implementation success of an intensity adapted clinical practice guideline (CPG) based upon recommendations by the International Society of Paediatric Oncology (SIOP) for childhood AML in resource limited settings.

    CPG Implementation Success will be a composite endpoint comprised of:

    1. Feasibility: proportion of patients completing the CPG. (see Study Design for further details outlining CPG completion criteria)
    2. Effectiveness: proportion of patients in complete remission (CR) by the end of Induction 2 chemotherapy.

    Measured: From initiation of chemotherapy to assessment of completion of the CPG and attainment of end-of-induction bone marrow evaluation (if CPG completed to that point), assessed up to 12 months from the start of chemotherapy.

Secondary outcomes (10)

  1. Estimate the proportion of patients with negative minimal residual disease (MRD) following Induction

    MRD will be evaluated by bone marrow examination with multiparameter flow cytometry. MRD positivity will be defined as ≥0.1% residual pathological myeloblasts.

    Measured: By end of second induction, assessed up to 6 months from initiating chemotherapy.

  2. Estimate the proportion of patients with early mortality

    Early mortality is defined as death occurring ≤42 days from the beginning of treatment.

    Measured: Assessed up to 42 days from start of chemotherapy

  3. Estimate the proportion of patients with treatment-related mortality on the CPG

    TRM will be defined as death occurring >42 days from the beginning of treatment due to any cause in the absence of progressive cancer.

    Measured: Assessed from Day 43 following initiation of chemotherapy through to completion of the CPG, assessed up to 12 months.

  4. Estimate the proportion of patients with serious adverse events

    All adverse events among patients treated on the CPG will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5. All the Grade ≥3 adverse events will be recorded

    Measured: From initiation of chemotherapy through to completion of the CPG, assessed up to 12 months.

  5. Estimate the time to hematologic recovery following cycles of chemotherapy

    Time to transfusion independence of blood products following completion of therapy.

    Measured: From the final dose of curative-intent chemotherapy to blood product independence, assessed up to 6 months.

  6. Estimate the proportion of patients with treatment abandonment.

    After starting Day 1 of therapy, any unplanned hiatus of curative-intent therapy lasting ≥4 weeks lasting ≥4 weeks.

    Measured: From initiation of chemotherapy to completion of the CPG, assessed up to 12 months.

  7. Estimate survival of patients treated with the CPG.

    Overall, event-free, and relapse-free survival 12 \& 24 months from diagnosis.

    Measured: Assessed 24 months from start of therapy

  8. Describe myeloblast cytogenetics

    Myeloblast cytogenetics is defined as reported by NanoString bone marrow analysis at diagnosis.

    Measured: Time of diagnosis (samples are batched and assessed up to 6 months following diagnostic bone marrow evaluation)

  9. Describe Patient Reported Outcomes at relevant timepoints.

    Patient-Reported Outcomes Measurement Information System (PROMIS-25) questionnaires will be given to parents and children enrolled on study at the time of diagnosis (within 30 days) and at the end of second Induction (within 30 days). Questionnaires will be administered by study personnel while patients are inpatient. As many families at the treatment center are illiterate, all questionnaires will be read and filled in by study personnel based on answers by the parents/children.

    Measured: Assessed within 30 days of diagnostic bone marrow evaluation (diagnosis timepoints) and within 30 days of the end of second induction (mid-therapy time-point, assessed up to 6 months from diagnosis).

  10. Determine the fidelity to treatment and supportive care practice guidelines associated with AML therapy in Malawi

    Proportion of discrete treatment and supportive care guideline elements received/completed as prescribed.

    Measured: From initiation of chemotherapy through to completion of the CPG, assessed up to 12 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Apr 2025
  2. Study start1 Jan 2025
  3. Primary completion31 Dec 2028 (estimated)
  4. Study completion31 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06928909
Sponsor's protocol ID
H-53055
Acronym
LEAP
Status last verified
Jul 2026
First submitted
19 Mar 2025
Last updated
15 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Malawian data privacy laws prohibit open sharing of individual patient data. Aggregated data supporting study outcomes will be published as a scientific manuscript. Requests for IPD will be considered on a case-by-case basis by study investigators, following all applicable Malawian data privacy laws.

Publications

  • Banavali, S. D. et al. PRET: an effective oral protocol for out-patient therapy in patients with acute myeloid leukemia. International Society of Paediatric Oncology Meeting Abstracts (2004).

  • Malani D, Murumagi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11.

    PubMed 27833094

  • Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R, Hamamoto K, Imaizumi M, Morimoto A, Tsuchiya S, Hanada R. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009 Aug 20;27(24):4007-13. doi: 10.1200/JCO.2008.18.7948. Epub 2009 Jul 20.

    PubMed 19620491

  • Organization, W. H. World Cancer Day 2023: Message of the WHO Regional Director for Africa, Dr. Matshidiso Moeti. https://www.afro.who.int/regional-director/speechesmessages/ world-cancer-day-2023 (2023).

  • Van Weelderen RE, Klein K, Natawidjaja MD, De Vries R, Kaspers GJ. Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. Expert Rev Anticancer Ther. 2021 Jul;21(7):765-780. doi: 10.1080/14737140.2021.1895756. Epub 2021 Mar 29.

    PubMed 33779466

  • Roberts N, James S, Delaney M, Fitzmaurice C. The global need and availability of blood products: a modelling study. Lancet Haematol. 2019 Dec;6(12):e606-e615. doi: 10.1016/S2352-3026(19)30200-5. Epub 2019 Oct 17.

    PubMed 31631023

  • Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard J, Razzouk BI, Aplenc R, Kolb EA. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020 Jul 1;38(19):2170-2177. doi: 10.1200/JCO.19.03306. Epub 2020 May 13.

    PubMed 32401633

  • Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun;61(2):540-5. doi: 10.1111/j.1541-0420.2005.00311.x.

    PubMed 16011702

  • Einstein MH, Ndlovu N, Lee J, Stier EA, Kotzen J, Garg M, Whitney K, Lensing SY, Tunmer M, Kadzatsa W, Palefsky J, Krown SE. Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium. Gynecol Oncol. 2019 Apr;153(1):20-25. doi: 10.1016/j.ygyno.2019.01.023. Epub 2019 Feb 15.

    PubMed 30773222

  • Health, N. I. of. Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. httpsctep.cancer.govprotocolDevelopmentelectronicapplicationsctc.htm (2017).

  • Alexander S, Pole JD, Gibson P, Lee M, Hesser T, Chi SN, Dvorak CC, Fisher B, Hasle H, Kanerva J, Moricke A, Phillips B, Raetz E, Rodriguez-Galindo C, Samarasinghe S, Schmiegelow K, Tissing W, Lehrnbecher T, Sung L; International Pediatric Oncology Mortality Classification Group. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol. 2015 Dec;16(16):e604-10. doi: 10.1016/S1470-2045(15)00197-7.

    PubMed 26678213

  • Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung L, Stary J, Zwaan CM, Kaspers GJ, Reinhardt D; AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012 Oct 18;120(16):3187-205. doi: 10.1182/blood-2012-03-362608. Epub 2012 Aug 9.

    PubMed 22879540

  • Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.

    PubMed 35732831

  • Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7.

    PubMed 20957426

  • Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.

    PubMed 22310560

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Myeloid Leukaemia, run by Baylor College of Medicine at 1 site in Malawi.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Malawi. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Casey McAtee, M.D., M.P.H. (+1 251-605-5370, casey.mcatee@bcm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determine the implementation success of an intensity adapted clinical practice guideline (CPG) based upon recommendations by the International Society of Paediatric Oncology (SIOP) for childhood AML in resource limited settings. (time frame: From initiation of chemotherapy to assessment of completion of the CPG and attainment of end-of-induction bone marrow evaluation (if CPG completed to that point), assessed up to 12 months from the start of chemotherapy.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06928909, which also lists 47 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in